Oncology Medications


(ropeginterferon alfa-2b-njft) Injection

Onco360 is a trusted specialty pharmacy partner for BESREMi®, the first and only FDA-approved treatment for polycythemia vera (PV)

Onco360 understands the importance of working with your patients closely to avoid PV progression, and we are here to help. We provide ongoing and personalized support to ensure the best clinical expertise, medication adherence, and side effect management.

BESREMi (ropeginterferon alfa-2b-njft) is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera by targeting the source of the disease.

BESREMi is not chemotherapy. It is a bi-weekly injection that targets the bone marrow and may help control blood cell counts. That’s what makes BESREMi unique. It addresses the cause of PV. The injection is a 500mcg/mL solution in a single-dose prefilled syringe (NDC 73536-500-01).

Dosage and Administration1 

  • Recommended starting dose: 100 mcg by subcutaneous injection every 2 weeks (50 mcg if receiving hydroxyurea)
  • Increase the dose by 50 mcg every 2 weeks (up to a maximum of 500 mcg) until hematological parameters are stabilized
  • Interrupt or discontinue dosing if certain adverse reactions occur

Watch BESREMi’s video with step-by-step instructions for self-injection: Watch Now

Trust the pharmacy experts at Onco360.
3 Easy Ways to Refer:


Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis


How to Refer